α2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 10, 2008, Pages 4515-4522

  Dong, Cun Jian ^a   Guo, Yuanxing ^a   Agey, Peter ^a   Wheeler, Larry ^a   Hare, William A ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; ADENYLATE CYCLASE ACTIVATOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATIPAMEZOLE; BRIMONIDINE; CALCIUM ION; CYCLIC AMP; CYCLIC AMP DERIVATIVE; DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; CALCIUM; N METHYLASPARTIC ACID; NEUROPROTECTIVE AGENT; QUINOXALINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM SIGNALING; CELL PROTECTION; CONTROLLED STUDY; CYTOSOL; EXCITOTOXICITY; EYE PROTECTION; GLAUCOMA; IN VITRO STUDY; IN VIVO STUDY; ISOLATED RETINA; MALE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; RETINA DISEASE; RETINA GANGLION CELL; VOLTAGE CLAMP; WHOLE CELL; ANIMAL; BROWN NORWAY RAT; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; RABBIT; RETINA; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CALCIUM; CALCIUM SIGNALING; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; GLAUCOMA; MALE; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; PHOSPHODIESTERASE INHIBITORS; QUINOXALINES; RABBITS; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, N-METHYL-D-ASPARTATE; RETINA; RETINAL GANGLION CELLS; ROLIPRAM;

EID: 53449088505     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2078     Document Type: Article

References (49)

1. Peterhoff M, Sieg A, Brede M, Chao CM, Hein L, Ullrich S. Inhibition of insulin secretion via distinct signaling pathways in α2-adrenoceptor knockout mice. Eur J Endocrinol. 2003;149:343-350. (Pubitemid 37304706)
2. Moura E, Afonso J, Hein L, Vieira-Coelho MA. α2-Adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol. 2006;149:1049-1058. (Pubitemid 44950808)
3. Scheibner J, Trendelenburg AU, Hein L, Starke K. α2-Adrenoceptors modulating neuronal serotonin release: a study in α2-adrenoceptor subtype-deficient mice. Br J Pharmacol. 2001;132:925-933. (Pubitemid 32193650)
4. Pan YZ, Li DP, Pan HL. Inhibition of glutamatergic synaptic input to spinal lamina II(o) neurons by presynaptic alpha(2)-adrenergic receptors. J Neurophysiol. 2002;87:1938-1947.
5. Maze M. α2 Adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology. 1991;74:681-1605
6. Starke K. Presynaptic autoreceptors in the third decade: focus on α2-adrenoceptors. J Neurochem. 2001;78:685-693. (Pubitemid 32777970)
7. Ma D, Rajakumaraswamy N, Maze M. α2-Adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull. 2005;71:77-92.
8. Delaney AJ, Crane JW, Sah P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron. 2007;56:880-892. (Pubitemid 350181353)
9. Sanders RD, Maze M. α2-Adrenoceptor agonists. Curr Opin Investig Drugs. 2007;8:25-33.
10. Haddad JJ. N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention? Prog Neurobiol. 2005;77:252-282.
11. Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist. 2005;11:37-49.
12. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope. Pharmacol Res. 2005;51:1-17. (Pubitemid 39425068)
13. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2007;81:272-293.
14. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001;429:71-78.
15. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician. 2007;10:493-500. (Pubitemid 46971302)
16. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma. 2002;11:474-480. (Pubitemid 36015103)
17. Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest Ophthalmol Vis Sci. 2004;45:2625-2629. (Pubitemid 38998859)
18. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci. 2004;45:2640-2651. (Pubitemid 38998860)
19. Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol. 2001;24:107-129. (Pubitemid 34066681)
20. Nakamichi N, Oikawa H, Kambe Y, Yoneda Y. Relevant modulation by ferrous ions of N-methyl-D-aspartate receptors in ischemic brain injuries. Curr Neurovasc Res. 2004;1:429-440.
21. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849-2855. (Pubitemid 33035282)
22. Kim HS, Chang YI, Kim JH, Park CK. Alteration of retinal intrinsic survival signal and effect of α2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat. Vis Neurosci. 2007;24:127-139.
23. ++ signals at the inner plexiform layer of the rat retina. Invest Ophthalmol Vis Sci. 2007;48:1410-1415.
24. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. α(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296:216-223.
25. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005;89:758-763.
26. Grünert U, Haverkamp S, Fletcher EL, Wässle H. Synaptic distribution of ionotropic glutamate receptors in the inner plexiform layer of the primate retina. J Comp Neurol. 2002;447:138-151. (Pubitemid 34457375)
27. Sun D, Rait JL, Kalloniatis M. Inner retinal neurons display differential responses to N-methyl-D-aspartate receptor activation. J Comp Neurol. 2003;465:38-56. (Pubitemid 37075679)
28. Heidinger V, Manzerra P, Wang XQ, et al. Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci. 2002;22:5452-5461. (Pubitemid 35386467)
29. Lipton SA, Choi YB, Takahashi H, et al. Cysteine regulation of protein function- as exemplified by NMDA receptor modulation. Trends Neurosci. 2002;25:474-489. (Pubitemid 35223002)
30. Sanchez-Perez A, Llansola M, Cauli O, Felipo V. Modulation of NMDA receptors in the cerebellum, II: signaling pathways and physiological modulators regulating NMDA receptor function. Cerebellum. 2005;4:162-170. (Pubitemid 41354425)
31. MacDonald JF, Jackson MF, Beazely MA. G protein-coupled receptors control NMDARs and metaplasticity in the hippocampus. Biochim Biophys Acta. 2007;1768:941-951.
32. Han Y, Wu SM. NMDA-evoked [Ca2+]i increase in salamander retinal ganglion cells: modulation by PKA and adrenergic receptors. Vis Neurosci. 2002;19:249-256. (Pubitemid 36221905)
33. Baptiste DC, Hartwick AT, Jollimore CA, et al. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci. 2002;43:2666-2676.
34. Liu W, Yuen EY, Allen PB, Feng J, Greengard P, Yan Z. Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin. Proc Natl Acad Sci USA. 2006;28:103:18338-18343. (Pubitemid 44871659)
35. 2+ channels in rat sympathetic neurones. J Physiol. 1999;518:23-36.
36. Davies J, Watkins JC. Actions of D and L forms of 2-amino-5- phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 1982;235:378-386. (Pubitemid 12180787)
37. Virtanen R. Pharmacological profiles of medetomidine and its antagonist atipamezole. Acta Vet Scand Suppl. 1989;85:29-37.
38. MacDonald E, Kobilka BK, Scheinin M. Gene targeting - homing in on α2-adrenoceptor-subtype function. Trends Pharmacol Sci. 1997;18:211-219. (Pubitemid 27283651)
39. De Souza NJ, Dohadwalla AN. Forskolin: A labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev. 1983;3:201-219.
40. Kucera GL, Rittenhouse SE. Inhibition of GDP beta S of agonist-activated phospholipase C in human platelets requires cell permeabilization. Biochem Biophys Res Commun. 1988;153:417-421.
41. Thompson WJ, Anderson PS, Britcher SF, et al. Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists. J Med Chem. 1990;33:789-808. (Pubitemid 20047610)
42. Collingridge GL, Lester RAJ. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev. 1989;40:143-210. (Pubitemid 20019600)
43. Teixeira MM, Gristwood RW, Nicola C, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci. 1997;18:164-171.
44. O'Brian CA, Roczniak SO, Bramson HN, Baraniak J, Stec WJ, Kaiser ET. A kinetic study of interactions of (Rp)- and (Sp)-adenosine cyclic 3′,5′-phosphorothioates with type II bovine cardiac muscle adenosine cyclic 3′,5′-phosphate dependent protein kinase. Biochemistry. 1982;21:4371-4376.
45. Fabbri E, Brighenti L, Ottolenghi C. Inhibition of adenylate cyclase of catfish and rat hepatocyte membranes by 9-(tetrahydro-2-furyl) adenine (SQ 22536). J Enzyme Inhib. 1991;5:87-98.
46. Kohl BK, Dannhardt G. The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr Med Chem. 2001;8:1275-1289. (Pubitemid 32791797)
47. Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol. 2007;21:259-271.
48. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007;6:101-115. (Pubitemid 46681771)
49. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5:160-170.